Methods
The co-medications included in this review concern diseases with a high
prevalence or occurrence, and those commonly associated with HIV/AIDS
and considered critical for patient care in sub-Saharan Africa. The WHO
2021 Model List of Essential Medicines was consulted to identify drugs
of interest to our review .
Once the list of co-medications was identified, a literature search was
conducted on PubMed using a predefined Boolean search strategy. The
search strategy described below (Table 1) was used to identify relevant
studies published up until April 2023. The search was limited to studies
conducted in humans or PBPK simulation, published in English. All
potentially related designs, including trials, observational studies,
experimental and in silico studies, were considered in the
literature search. Studies were not restricted to a particular
geographical area.
In addition to the literature search, the Liverpool HIV drug interaction
database was consulted to identify additional studies on DDIs between
cabotegravir or rilpivirine and the predefined co-medications. This
database provides a comprehensive resource for healthcare professionals,
researchers, and patients to identify potential drug interactions
between antiretrovirals and other medications used in clinical practice.
By consulting this database, we aimed to supplement the literature
search and ensure that all relevant information on potential DDIs was
captured.